| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/13/2005 | CA2527905A1 Nadks as modifiers of branching morphogenesis and methods of use |
| 01/12/2005 | EP1495327A2 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495117A2 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 01/12/2005 | EP1495113A2 Stimulation of nerve cell regeneration |
| 01/12/2005 | EP1495053A2 Angiopoietin-2 specific binding agents |
| 01/12/2005 | EP1495042A1 Blanched polyamine steroid derivatives |
| 01/12/2005 | EP1495026A1 Methods and compositions comprising nitric oxide donors and opioid analgesics |
| 01/12/2005 | EP1494756A2 Chemiluminescent treatment of acne |
| 01/12/2005 | EP1494730A1 Composition for hard tissue augmentation |
| 01/12/2005 | EP1494718A1 Combination of an agent that attenuates topoisomerase i activity and an agent that inhibits heat shock protein 90 for use in chemotherapy |
| 01/12/2005 | EP1494716A2 Use of substances for treating tumors |
| 01/12/2005 | EP1494715A1 Fp receptor antagonists or pgf2 aplha antagonists for treating menorrhagia |
| 01/12/2005 | EP1494713A2 Methods for treating tweak-related conditions |
| 01/12/2005 | EP1494709A2 Compositions and methods for the diagnosis and treatment of tumor |
| 01/12/2005 | EP1494706A2 Antimicrobial polymer conjugates |
| 01/12/2005 | EP1494705A1 A composition and method for killing of tumours |
| 01/12/2005 | EP1494704A1 Glp-1 agonist and cardiovascular complications |
| 01/12/2005 | EP1494701A2 Immunosuppressant compounds, methods and uses related thereto |
| 01/12/2005 | EP1494698A2 Compositions and methods for treating and preventing necrosis |
| 01/12/2005 | EP1494691A2 Treatment of diseases involving defective gap junctional communication |
| 01/12/2005 | EP1494688A1 Use of topical compositions for the control of microbial diseases of the nail |
| 01/12/2005 | EP1494685A1 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| 01/12/2005 | EP1494684A2 USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY |
| 01/12/2005 | EP1494683A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| 01/12/2005 | EP1494677A1 Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction |
| 01/12/2005 | EP1494676A1 Fused quinoxaline derivatives as inhibitors of akt activity |
| 01/12/2005 | EP1494668A2 Use of benzimidazole analogs in the treatment of cell proliferation |
| 01/12/2005 | EP1494666A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant |
| 01/12/2005 | EP1494665A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| 01/12/2005 | EP1494664A2 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
| 01/12/2005 | EP1494662A1 Tnp-470 polymer conjugates and use thereof |
| 01/12/2005 | EP1494650A1 Pharmaceutical formulation comprising melatonin |
| 01/12/2005 | EP1494649A1 Nanoparticulate megestrol formulations |
| 01/12/2005 | EP1494645A2 Method of treating mucus hypersecretion |
| 01/12/2005 | EP1494644A1 Dry powder compositions |
| 01/12/2005 | EP1494634A1 Controlled delivery patch of active ingredient |
| 01/12/2005 | EP1494630A2 Bioadhesive drug delivery system |
| 01/12/2005 | EP1494542A1 Composition for modulating a physiological reaction or inducing an immune response |
| 01/12/2005 | EP1494536A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 01/12/2005 | EP1494530A2 Combination therapy using trefoil peptides |
| 01/12/2005 | EP1443970A4 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/12/2005 | EP1434773A4 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 01/12/2005 | EP1365781A4 Acrochordon alleviation |
| 01/12/2005 | EP1307216A4 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/12/2005 | EP1233023B1 Transcription factor and dna thereof |
| 01/12/2005 | EP1227797B1 Solid dispersion pharmaceutical formulations |
| 01/12/2005 | EP1227734B1 Compositions comprising edible oils or fats and phytosterols and/or phytostanols dissolved therein |
| 01/12/2005 | EP1226212A4 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 01/12/2005 | EP1194122B1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/12/2005 | EP1183228B1 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds. |
| 01/12/2005 | EP1089713B1 Temperature-sensitive liposomal formulation |
| 01/12/2005 | EP1063987A4 Dietary control of arachidonic acid metabolism |
| 01/12/2005 | EP1005333B1 Methods and compositions for preventing and treating chronological aging in human skin |
| 01/12/2005 | EP0996460B1 Treatment of kidney fibrosis with antibodies against integrin alpha-v-beta 6 |
| 01/12/2005 | EP0891428B1 Phosphatidylinositol 3-kinase p110 delta catalytic subunit |
| 01/12/2005 | CN1564829A Antibodies to insulin-like growth factor I receptor |
| 01/12/2005 | CN1564826A Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 01/12/2005 | CN1564696A Compositions for and methods of treating and preventing sirs/sepsis |
| 01/12/2005 | CN1564689A Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 01/12/2005 | CN1564688A Methods of treating pulmonary disease |
| 01/12/2005 | CN1564683A Methods for treating dry eye by a combination of an antiinflammatory steroid and a MUC-1 secretagogue |
| 01/12/2005 | CN1564678A Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 01/12/2005 | CN1564676A Invert emulsion containing DHEA |
| 01/12/2005 | CN1562370A Antiphlogistic and antirheumatic compound preparation |
| 01/12/2005 | CN1562369A Combination of medication for curing high blood pressure |
| 01/12/2005 | CN1184321C Adenovirus-mediated gene therapy |
| 01/12/2005 | CN1184204C Piperidine compounds for use as CCR-3 inhibitors |
| 01/12/2005 | CN1183901C Pharmaceutical compositions capable of being gelled |
| 01/11/2005 | US6841579 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/11/2005 | US6841578 Administering a an inhibitor of nuclear factor-kappa B to an individual undergoing or preparing to undergo a treatment for cancer; particularly ulcerative mouth tissue; antiinflammatory agents; side effect reduction |
| 01/11/2005 | US6841566 Viral polymerase inhibitors |
| 01/11/2005 | US6841564 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/11/2005 | US6841561 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 01/11/2005 | US6841551 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle |
| 01/11/2005 | US6841544 Composition and method for treating the effects of diseases and maladies |
| 01/11/2005 | US6841371 Comprises anticoagulant polypeptide for treatment and prevention of acute coronary syndromes, vascular occlusive disorders and thrombosis |
| 01/11/2005 | US6841345 Reducing lymphadenopathy associated viral replication in monocytes; viricides |
| 01/11/2005 | US6841161 Topical compositions |
| 01/11/2005 | US6840244 Condom with an erectogenic composition |
| 01/11/2005 | CA2241244C Use of inhibitors of the activity of retinoic acid for treating sensitive skin and/or acute damage induced by uv radiation |
| 01/07/2005 | CA2470768A1 Crystal structure of osc |
| 01/06/2005 | WO2005002224A1 Circuit for processing video signal containing information such as closed caption |
| 01/06/2005 | WO2005001038A2 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | WO2005001033A2 Tolerance induction and maintenance in hematopoietic stem cell allografts |
| 01/06/2005 | WO2005001022A2 Methods and compositions for enhancing immune response |
| 01/06/2005 | WO2005000900A1 Treatment with anti-vegf antibodies |
| 01/06/2005 | WO2005000852A2 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 01/06/2005 | WO2005000357A2 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/06/2005 | WO2005000356A1 Remedy for urinary tract diseases |
| 01/06/2005 | WO2005000355A1 Treatment of tumor by cotransferring chemotherapeutic agent with cytokine gene |
| 01/06/2005 | WO2005000354A1 Preventive/remedy for urinary disturbance |
| 01/06/2005 | WO2005000353A1 Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis |
| 01/06/2005 | WO2005000341A1 Use of cytosolic phospholipid hydroperoxide glutathione peroxidase to reduce tumor growth |
| 01/06/2005 | WO2005000337A1 Compositions and methods for treatment of rosacea |
| 01/06/2005 | WO2005000331A2 Compositions for the treatment and prevention of degenerative joint disorders |
| 01/06/2005 | WO2005000324A2 Colloidal silver composition having antimicrobial properties |
| 01/06/2005 | WO2005000323A1 Chemical composition of the natural composite developed for energetic and cellular structuring and/or restructuring |
| 01/06/2005 | WO2005000318A2 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 01/06/2005 | WO2005000315A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h3 and an antipsychotic or antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |